Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Base impedance, an indicator of cell viability, can be used to non-invasively identify structural and functional cardiotoxicity over a chronic time course.
We have developed a chronic cardiotoxicity assay using human hiPSC-derived cardiomyocytes, which has been validated with a number of cardiotoxicants. For example, doxorubicin, a member of the anthracycline family that is used to treat breast cancer, is associated with a number of cardiac side effects, which includes acute atrial and ventricular arrhythmias, chronic cardiomyopathy and congestive heart failure.
This chronic cardiotoxicity assay recapitulates doxorubicin’s cardiotoxic effect by producing a concentration-dependent decrease of base impedance that develops following a 24 hour exposure period.
Figure 1. Effects of Doxorubicin on hiPSC impedance.
Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50